Drug controls

Reports on a study that calls on the federal government to tighten regulations on drugs being tested and prescribed to prevent disease.

Examines the Canadian system of adverse drug reactions reporting and that women’s particular susceptibilities to drug-related health risks must be taken into consideration.

Examines the question of harmonisation of pharmaceutical regulation and its implications for women and public health. Urges that safety standards be paramount and the particular needs of women and other groups are not lost.

Explains how the push to streamline the drug approval process in the world's three largest pharmaceutical markets is neglecting the special needs of women.

Outlines concerns about direct-to-consumer advertising, including lack of public regulation and targeting of already healthy populations.

Summarizes the papers and discussions which took place during the 1996 Health Action International and BUKO Pharma-Kampagne seminar on the subject of the GATT/World Trade Organization, Pharmaceutical Policies and Essential Drugs.

Discusses the origins of confidentiality in drug regulation, the scope of regulations, the development and consequence of excessive secrecy in drug regulation, the benefits of openness of drug information, and the need for transparency at the international level.